CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Industry Trade Show
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
15-16 June, 2026
Digital content

30 Oct 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219955

17 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hikma-acquires-novugens-fda-approved-anda-for-trametinib-302431694.html

24 Apr 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218231

21 Aug 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218012
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the acquisition, Hikma holds the rights of Mekinist-Generic (trametinib dimethyl sulfoxide) tablets from Novugen. It is being indicated for the treatment of BRAF-mutated melanoma.
Lead Product(s): Trametinib
Therapeutic Area: Oncology Brand Name: Mekinist-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Trametinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Hikma acquires Novugen's FDA-approved ANDA for trametinib
Details : Through the acquisition, Hikma holds the rights of Mekinist-Generic (trametinib dimethyl sulfoxide) tablets from Novugen. It is being indicated for the treatment of BRAF-mutated melanoma.
Product Name : Mekinist-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 17, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : ABIRATERONE ACETATE
Dosage Strength : 250MG
Approval Date : 2022-01-05
Application Number : 215947
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : ABIRATERONE ACETATE
Dosage Strength : 500MG
Approval Date : 2022-01-05
Application Number : 215947
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : EVEROLIMUS
Dosage Strength : 2.5MG
Approval Date : 2025-10-30
Application Number : 219955
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : EVEROLIMUS
Dosage Strength : 5MG
Approval Date : 2025-10-30
Application Number : 219955
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : EVEROLIMUS
Dosage Strength : 7.5MG
Approval Date : 2025-10-30
Application Number : 219955
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : TABLET; ORAL
Proprietary Name : EVEROLIMUS
Dosage Strength : 10MG
Approval Date : 2025-10-30
Application Number : 219955
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : CAPSULE; ORAL
Proprietary Name : LENALIDOMIDE
Dosage Strength : 2.5MG
Approval Date : 2024-09-11
Application Number : 217281
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : CAPSULE; ORAL
Proprietary Name : LENALIDOMIDE
Dosage Strength : 5MG
Approval Date : 2024-09-11
Application Number : 217281
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : CAPSULE; ORAL
Proprietary Name : LENALIDOMIDE
Dosage Strength : 10MG
Approval Date : 2024-09-11
Application Number : 217281
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Dosage Form : CAPSULE; ORAL
Proprietary Name : LENALIDOMIDE
Dosage Strength : 15MG
Approval Date : 2024-09-11
Application Number : 217281
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

ABOUT THIS PAGE
Novugen is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find Albendazole bulk with DMF offered by Novugen
Find Fingolimod Hydrochloride bulk with DMF offered by Novugen
Find Solifenacin Succinate bulk with DMF offered by Novugen